Literature DB >> 8635871

Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line.

G Baldassarre1, C Bianco, G Tortora, A Ruggiero, M Moasser, E Dmitrovsky, A R Bianco, F Ciardiello.   

Abstract

CRIPTO is a member of the epidermal growth factor (EGF) gene family originally isolated from undifferentiated human NTERA2 clone D1 (NT2D1) multipotent embryonal carcinoma cells. Retinoic acid (RA) treatment of NT2D1 cells leads to a neuronal differentiation program and to concomitant loss of CRIPTO mRNA expression. To assess the role of CRIPTO in the control of NT2D1 cell growth or differentiation, these cells were treated with 3 anti-sense oligodeoxynucleotides complementary to the 5' end of the human CRIPTO mRNA. A dose-dependent inhibition of monolayer and soft agar growth was observed with each of these CRIPTO anti-sense oligodeoxynucleotides but not with a control oligodeoxynucleotide of random sequence or with the 3 corresponding CRIPTO sense oligodeoxynucleotides. In addition, NT2D1 cells were transfected with a recombinant expression vector containing a 918-bp coding fragment of the human CRIPTO cDNA in the 3' to 5' orientation. NT2D1 CRIPTO anti-sense transfectants exhibited a significantly reduced endogenous CRIPTO mRNA and protein, a 4- to 5-fold decrease in growth rate in monolayer and a 50-70% reduction in cloning efficiency in soft agar as compared with NT2D1 parental cells or with NT2D1 cells transfected with a plasmid containing the neomycin-resistance gene alone (NT2D1 neo cells). Finally, we examined the expression of immunophenotypic markers that are modulated during the differentiation of NT2D1 cells following RA treatment. The globoseries stage-specific embryonic antigen-3 recognized by the monoclonal antibody (MAb) SSEA-3 was expressed in 60% of undifferentiated parental NT2D1 or NT2D1 neo cells and in only 20% of NT2D1 CRIPTO anti-sense transfectants, whereas it was down-regulated in all cell lines following RA treatment. A neuroectodermal antigen recognized by the A2B5 MAb, which was not expressed in parental NT2D1, in NT2D1 neo or in CRIPTO anti-sense NT2D1 cells, was induced by RA treatment in all cell lines. Taken together, our results show that inhibition of endogenous CRIPTO expression in human embryonal carcinoma cells interferes with both transformation and differentiation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8635871     DOI: 10.1002/(SICI)1097-0215(19960516)66:4<538::AID-IJC19>3.0.CO;2-3

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Current methods and challenges in the comprehensive characterization of human pluripotent stem cells.

Authors:  Joanna S T Asprer; Uma Lakshmipathy
Journal:  Stem Cell Rev Rep       Date:  2015-04       Impact factor: 5.739

2.  The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells.

Authors:  F Bost; R McKay; M Bost; O Potapova; N M Dean; D Mercola
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

3.  Enhancement of human embryonic stem cell pluripotency through inhibition of the mitochondrial respiratory chain.

Authors:  S Varum; O Momcilović; C Castro; A Ben-Yehudah; J Ramalho-Santos; C S Navara
Journal:  Stem Cell Res       Date:  2009-08-03       Impact factor: 2.020

4.  Interplay between SIN3A and STAT3 mediates chromatin conformational changes and GFAP expression during cellular differentiation.

Authors:  Pei-Yi Cheng; Yu-Ping Lin; Ya-Ling Chen; Yi-Ching Lee; Chia-Chen Tai; Yi-Ting Wang; Yu-Ju Chen; Cheng-Fu Kao; John Yu
Journal:  PLoS One       Date:  2011-07-11       Impact factor: 3.240

5.  A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth.

Authors:  Hiroko Ishii; Maram H Zahra; Atushi Takayanagi; Masaharu Seno
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

6.  Lefty blocks a subset of TGFbeta signals by antagonizing EGF-CFC coreceptors.

Authors:  Simon K Cheng; Felix Olale; Ali H Brivanlou; Alexander F Schier
Journal:  PLoS Biol       Date:  2004-02-17       Impact factor: 8.029

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.